{"organizations": [], "uuid": "637823a492e7d0d5a67efcf7462b2095e2d2b399", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180501.html", "section_title": "Archive News &amp; Video for Tuesday, 01 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-rigel-pharmaceuticals-q1-loss-per/brief-rigel-pharmaceuticals-q1-loss-per-share-0-17-idUSASC09YPF", "country": "US", "domain_rank": 408, "title": "BRIEF-Rigel Pharmaceuticals Q1 Loss Per Share $0.17", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.014, "site_type": "news", "published": "2018-05-02T04:49:00.000+03:00", "replies_count": 0, "uuid": "637823a492e7d0d5a67efcf7462b2095e2d2b399"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-rigel-pharmaceuticals-q1-loss-per/brief-rigel-pharmaceuticals-q1-loss-per-share-0-17-idUSASC09YPF", "ord_in_thread": 0, "title": "BRIEF-Rigel Pharmaceuticals Q1 Loss Per Share $0.17", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "rigel pharmaceuticals inc", "sentiment": "negative"}, {"name": "brief-rigel pharmaceuticals", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Rigel Pharmaceuticals Inc:\n* RIGEL ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE\n* Q1 LOSS PER SHARE $0.17 * Q1 EARNINGS PER SHARE VIEW $-0.18 â€” THOMSON REUTERS I/B/E/S\n* AS OF MARCH 31, HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $94.3 MILLION, VERSUS $115.8 MILLION AS OF DEC 31, 2017\n* RIGEL - EXPECTS CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TO BE SUFFICIENT THROUGH AT LEAST NEXT 12 MONTHS Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-02T04:49:00.000+03:00", "crawled": "2018-05-02T15:47:14.047+03:00", "highlightTitle": ""}